Novartis' Advair knockoff nabs Belgian nod; Actelion could go head-to-head with Gilead hopeful; Merck KGaA inks deal in Mozambique;

@FiercePharma: AstraZeneca's stateside comeback for Brilinta has run aground on a DoJ investigation. Story | Follow @FiercePharma

@TracyStaton: Team effort here - The most influential people in biopharma today. Report | Follow @TracyStaton

@EricPFierce: Hospira CEO F. Michael Ball says the FDA has moved its Austin, TX and Rocky Mount, NC facilities to VAI status. | Follow @EricPFierce

@CarlyHFierce: Can't make an influentials list without Valeant CEO J. Michael Pearson - that M&A strategy has made waves. More | Follow @CarlyHFierce

> AirFluSal Forspiro, a generic version of Advair from Novartis' ($NVS) Sandoz unit, won approval for sale in Belgium for patients with asthma or chronic obstructive pulmonary disease. Report

> Actelion's new drug for pulmonary arterial hypertension, Opsumit, may face a head-to-head trial with Gilead Sciences' ($GILD) experimental treatment for the same condition. Report

> Germany-based Merck has teamed up with the government of Mozambique to train med students and others on treating diabetes and other chronic illnesses. Report

> Hikma Pharmaceuticals chose Said Darwazah, its CEO, to take on the role of chairman as well; non-executive Chairman Samih Darwazah is retiring. Report

> Pakistan's pharma industry fears a shortage of a number of drug products because of government red tape on active ingredients for narcotics. Report

> A U.S. judge blocked warrantless searches of an Oregon state database of prescription drug records. Report

Medical Device News

@FierceMedDev: Italian Dx outfit DiaSorin launched a new Rotavirus test in the EU - it could have legs in the developing world, too. Story | Follow @FierceMedDev

@MarkHFierce: Folks, we have a strong new issue of FierceDiagnostics ready for reading. News from Myriad, Brazil and more. Issue | Follow @MarkHFierce

@MichaelGFierce: Who are the most influential people in biopharma today? Check out FierceBiotech's 2014 list. Report | Follow @MichaelGFierce

@EmilyWFierce: King Richard III's genome to be sequenced by researchers at the University of Leicester. Article | Follow @EmilyWFierce

> FDA publishes its warning letter to Baxter over home dialysis and infusion devices. Story

> NC patients exposed to rare, fatal brain disease through dirty surgical tools. More

> Sequoia Capital leads $10M round for cancer Dx startup Guardant Health. Item

> The FDA hit Amgen with a warning over drug/device combo manufacturing violations. News

Biotech News

@FierceBiotech: As many as 5 life sciences companies could go public this week, bringing in a combined $115M. News | Follow @FierceBiotech

@JohnCFierce: Really enjoyed talking with One Nucleus members about biotech valuations. Interesting times. | Follow @JohnCFierce

@DamianFierce: The most influential people in biopharma today, according to FierceBiotech. Who'd we miss? Who doesn't belong? | Follow @DamianFierce

@EmilyMFierce: Penn cancer research Carl June made our list of most influential people in biopharma. Profile | Follow @EmilyMFierce

> Third Rock puts up $45M for a voyage into gene therapy. Story

> Aggressive Gilead considers head-to-head PAH showdown with Actelion. Article

Drug Delivery News

> CalTech: Antibody carriers grant HIV protection across mucosal membranes. More

> To fight muscular dystrophy, nanoparticles target cells that choke themselves with waste. Story

> BioDelivery looks for $60M offering to boost addiction film, pain gel. News

> Alnylam, MIT team develops RNA-delivering nanoparticles for the liver. Report

> Nasal vaccine delivery conquers West Nile Virus in fewer doses. Article

> Sonrgy grabs rights to UCSD-created ultrasound-nanocarrier tech. Item

Diagnostics News

> Guardant Health raises $10M and debuts a new blood Dx for personalized cancer treatment. Story

> One Brazilian Dx giant gets new majority shareholders, and another may be sold. News

> Scottish imaging agent startup raises a $6.56 million Series A round. More

> Myriad and Gene By Gene resolve their differences over BRCA cancer Dx tests. Article

> Exact will make its case on March 27 for FDA approval of a colon cancer Dx. Piece

> Alere improves Q4 numbers through revenue growth and cost cuts. Item

Pharma Marketing News

> Steering for a U.S. comeback, AstraZeneca's Brilinta runs aground on DoJ investigation. Story

> Will PBMs turn copay coupons into an endangered species? Article

> Big Pharma legal whiz sees DoJ, FDA crackdown on CEO quotes and press releases. Story

> Feds target Teva in probe of Copaxone, Azilect marketing. News

> Nestlé plans to use its global marketing juju to rev up Galderma. Article

> New NICE advice could put millions more U.K. patients on statins. Item

And Finally... A huge new study casts more doubt on the value of mammograms. Report

Suggested Articles

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.